Yeda Research and Develpment & Co. Ltd

Rosetta Genomics Ltd.

Deutsches Krebsforschungszentrum

Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science

Moshe Oren

Varda Rotter

Perry Tal

Yael Spector

Nina Raver-Shapira

Efi Marciano

Peter Krammer

Benjamin Geiger

Zvi Kam

Avi Ben-Shimon

Ami Navon

Martina Muller-Schilling

Shay Eizenberger

Irina Lavelin

Yeal Spector

An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.

Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53

The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.

Peptides capable of reactivating p53 mutants

A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.

Proteasome inhibitors and uses thereof

Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.

Composition and methods for modulating cell proliferation and cell death

The present invention relates to p53 binding regions on a CD95 receptor DNA and to the application of the p53 binding regions to influence apoptosis and/or identify suitable substances therefor.

p53 binding areas

Growing community of inventors

Rehovot, Israel

Moshe Oren